Prisma Health-Midlands
Prisma Health-Midlands was paid $7.43M by Medicaid between Jan 2018 and May 2022, across 157 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 29% of everything it billed.
COULMBIA, SC 29203
Next to other General Acute Care Hospital providers in South Carolina
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 99,546 | $2.06M | |
| 2019 | 107,502 | $2.37M | |
| 2020 | 96,914 | $2.18M | |
| 2021 | 29,519 | $695K | |
| 2022 | 4,294 | $135K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 29% | 28,305 | 24,973 | $2.13M |
| 80053 | Comprehensive metabolic panel | 21% | 23,887 | 21,744 | $1.55M |
| 80081 | 6.7% | 2,967 | 2,576 | $494K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.3% | 11,107 | 9,964 | $395K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.4% | 4,174 | 3,318 | $326K |
| 86850 | 3.5% | 1,268 | 1,106 | $263K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.3% | 5,840 | 5,395 | $243K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.1% | 11,223 | 10,232 | $228K |
| 87480 | 3.0% | 2,981 | 2,752 | $222K | |
| 86780 | 2.5% | 4,953 | 4,530 | $186K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.8% | 12,662 | 11,276 | $132K |
| 87077 | 1.5% | 5,649 | 5,104 | $115K |
145 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 803 | $111K |
| 87070 | 1.5% | 3,801 | $108K | |
| 80061 | Lipid panel | 1.1% | 14,041 | $79K |
| 82785 | <1% | 1,276 | $64K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,647 | $47K |
| 87081 | <1% | 4,202 | $38K | |
| 84439 | <1% | 7,347 | $32K | |
| 82105 | <1% | 1,814 | $32K | |
| 86361 | <1% | 2,045 | $31K | |
| 80074 | <1% | 321 | $30K | |
| 83655 | <1% | 1,838 | $30K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,917 | $29K |
| 88142 | <1% | 3,664 | $24K | |
| 82950 | <1% | 3,729 | $23K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,315 | $23K |
| 87015 | <1% | 295 | $22K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 359 | $19K |
| 86003 | <1% | 1,441 | $19K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 24,196 | $18K |
| 87536 | <1% | 2,283 | $16K | |
| 83020 | <1% | 3,902 | $16K | |
| 80076 | <1% | 2,601 | $16K | |
| 82607 | <1% | 2,740 | $15K | |
| 86592 | <1% | 1,226 | $14K | |
| 86695 | <1% | 191 | $14K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,795 | $14K |
| 84702 | <1% | 1,310 | $14K | |
| 86706 | <1% | 1,191 | $13K | |
| 83001 | <1% | 803 | $13K | |
| 82728 | <1% | 2,961 | $12K | |
| 82040 | <1% | 378 | $10K | |
| 80069 | <1% | 1,493 | $10K | |
| 86038 | <1% | 1,508 | $9K | |
| 82570 | <1% | 2,461 | $9K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 55 | $8K |
| 82043 | <1% | 1,427 | $7K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 319 | $7K |
| 86803 | <1% | 4,333 | $7K | |
| 82784 | <1% | 2,014 | $6K | |
| 86704 | <1% | 569 | $6K | |
| 86481 | <1% | 713 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,114 | $6K |
| 84146 | <1% | 617 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 636 | $6K |
| 87631 | <1% | 46 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 317 | $5K |
| 82565 | <1% | 579 | $5K | |
| 85027 | <1% | 5,609 | $5K | |
| 86900 | <1% | 935 | $4K | |
| 87186 | <1% | 4,319 | $4K | |
| 86480 | <1% | 548 | $4K | |
| 83540 | <1% | 3,201 | $4K | |
| 83516 | <1% | 2,455 | $3K | |
| 82550 | <1% | 710 | $3K | |
| 81511 | <1% | 13 | $3K | |
| 80323 | <1% | 367 | $3K | |
| 82247 | <1% | 427 | $3K | |
| 82310 | <1% | 474 | $3K | |
| 86762 | <1% | 944 | $3K | |
| 86225 | <1% | 249 | $2K | |
| 84436 | <1% | 871 | $2K | |
| 86140 | <1% | 3,161 | $2K | |
| 87653 | <1% | 47 | $2K | |
| 84425 | <1% | 1,226 | $2K | |
| 80164 | <1% | 601 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,958 | $2K |
| 81001 | <1% | 2,913 | $2K | |
| 82951 | <1% | 315 | $2K | |
| 84550 | <1% | 1,035 | $2K | |
| 83014 | <1% | 27 | $2K | |
| 82670 | <1% | 57 | $1K | |
| 82272 | <1% | 13 | $1K | |
| 82746 | <1% | 1,930 | $1K | |
| 86708 | <1% | 278 | $1K | |
| 82627 | <1% | 71 | $1K | |
| 84153 | <1% | 446 | $1K | |
| 83993 | <1% | 50 | $1K | |
| 82947 | <1% | 293 | $1K | |
| 87045 | <1% | 92 | $1K | |
| 86696 | <1% | 257 | $1K | |
| 84403 | <1% | 547 | $1K | |
| 87660 | <1% | 2,937 | $905.29 | |
| 83013 | <1% | 82 | $793.02 | |
| 87510 | <1% | 2,980 | $745.04 | |
| 83735 | <1% | 2,844 | $719.04 | |
| 84450 | <1% | 675 | $717.98 | |
| 84156 | <1% | 1,614 | $698.20 | |
| 83880 | <1% | 294 | $651.08 | |
| 82977 | <1% | 408 | $628.43 | |
| 85652 | <1% | 3,607 | $619.75 | |
| 82465 | <1% | 85 | $536.03 | |
| 85610 | <1% | 1,328 | $534.65 | |
| 86665 | <1% | 62 | $527.00 | |
| 83970 | <1% | 601 | $480.22 | |
| 86160 | <1% | 570 | $437.02 | |
| 83002 | <1% | 511 | $421.66 | |
| 84305 | <1% | 161 | $380.13 | |
| 84466 | <1% | 1,457 | $378.80 | |
| 84481 | <1% | 829 | $346.47 | |
| 87205 | <1% | 1,572 | $321.94 | |
| 86901 | <1% | 930 | $319.01 | |
| 84134 | <1% | 1,430 | $310.69 | |
| 86235 | <1% | 180 | $264.65 | |
| 83615 | <1% | 221 | $233.92 | |
| 82157 | <1% | 45 | $220.18 | |
| 83525 | <1% | 366 | $169.16 | |
| 83690 | <1% | 519 | $164.33 | |
| 87340 | <1% | 2,629 | $139.61 | |
| 81025 | <1% | 131 | $137.46 | |
| 82397 | <1% | 13 | $132.57 | |
| 86431 | <1% | 592 | $132.55 | |
| 87338 | <1% | 17 | $131.13 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 28 | $126.12 |
| 86200 | <1% | 130 | $110.94 | |
| 87046 | <1% | 93 | $101.56 | |
| 84480 | <1% | 376 | $87.11 | |
| 86376 | <1% | 262 | $80.26 | |
| 80156 | <1% | 13 | $74.56 | |
| 82248 | <1% | 175 | $71.77 | |
| 87147 | <1% | 147 | $68.06 | |
| 87899 | <1% | 311 | $63.34 | |
| 87088 | <1% | 158 | $57.51 | |
| 85660 | <1% | 92 | $54.75 | |
| 82150 | <1% | 16 | $42.35 | |
| 80197 | <1% | 62 | $38.92 | |
| 86255 | <1% | 45 | $34.72 | |
| 82330 | <1% | 13 | $20.78 | |
| 86593 | <1% | 27 | $20.13 | |
| 86787 | <1% | 82 | $18.27 | |
| 82952 | <1% | 314 | $12.72 | |
| 84100 | <1% | 492 | $11.66 | |
| 84630 | <1% | 108 | $9.42 | |
| 81050 | <1% | 26 | $9.23 | |
| 84460 | <1% | 670 | $8.13 | |
| 81015 | <1% | 46 | $7.79 | |
| 85045 | 0% | 41 | $0.00 | |
| 86336 | 0% | 13 | $0.00 | |
| 86765 | 0% | 23 | $0.00 | |
| 83721 | 0% | 14 | $0.00 | |
| 84520 | 0% | 26 | $0.00 | |
| 83498 | 0% | 46 | $0.00 | |
| 86800 | 0% | 109 | $0.00 | |
| 87181 | 0% | 14 | $0.00 | |
| 85730 | 0% | 12 | $0.00 | |
| 82677 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Prisma Health-Midlands | Columbia, SC | $74.58M |
| Prisma Health-Midlands | Columbia, SC | $68.26M |
| Prisma Health-Upstate | Greenville, SC | $25.04M |
| Prisma Health-Upstate | Greenville, SC | $21.98M |
| Prisma Health-Upstate | Greenville, SC | $19.69M |
| Prisma Health-Upstate | Seneca, SC | $15.64M |
| Prisma Health-Midlands | Columbia, SC | $11.77M |
| Prisma Health-Upstate | Greenville, SC | $10.74M |
| Greenville Health Corporation | Greenville, SC | $8.90M |
| Prisma Health-Upstate | Greenville, SC | $8.32M |
| Prisma Health-Upstate | Greenville, SC | $7.45M |
| Prisma Health University Medical Group | Greenville, SC | $7.44M |
| Prisma Health-Midlands | Columbia, SC | $6.88M |
| Prisma Health Tuomey | Sumter, SC | $6.84M |
| Prisma Health-Midlands | Columbia, SC | $6.77M |
| Prisma Health-Upstate | Greenville, SC | $6.37M |
| Prisma Health-Upstate | Greenville, SC | $5.00M |
| Prisma Health-Upstate | Greenville, SC | $4.65M |
| Prisma Health-Midlands | Columbia, SC | $4.63M |
| Prisma Health-Upstate | Seneca, SC | $4.48M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.